Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin

RE-COVER, 2009 - dabigatran vs vitamin K antagonists

Romera, 2009 - Tinzaparin vs acenocoumarol

González-Fajardo, 2008 - Enoxaparin vs coumarin

Botticelli DVT, 2008 - apixaban vs heparin/VKA

Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA

VanGogh DVT, 2007 - idraparinux vs heparin/VKA

VanGogh PE, 2007 - idraparinux vs heparin/VKA

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Fiessinger , 2005 - ximelagatran vs vitamin K antagonists

Chong, 2005 - LMWH at home vs UFH in hospital

Kearon, 2004 - 4 months vs 3 months

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

MATISSE, 2004 - fondaparinux vs enoxaparin

Lee, 2003 - Dalteparin vs warfarin

Agnelli, 2003 - 6-12 months vs 3 months

Kakkar, 2003 - Bemiparin vs warfarin

Deitcher, 2003 - Enoxaparin vs warfarin

MATISSE PE, 2003 - fondaparinux vs heparin/VKA

Hull, 2002 - Tinzaparin vs warfarin

Meyer, 2002 - Enoxaparin vs warfarin

Agnelli, 2001 - 12 months vs 3 months

Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH

Lopez-Beret, 2001 - Nadroparin vs acenocoumarol

Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin



See also:

  • All venous thrombosis clinical trials
  •  

    Kearon study, 2004

    Treatments

    Studied treatment continuation for 2 additionnal months of warfarin adjusted to achieve a target INR between 2.0 and 3.0.
    Control treatment discontinuation (after 1 months)

    Patients

    Inclusion criteria first episode of idiopathic venous thromboembolism; DVT demonstrated by bilateral compression ultrasonography of the proximal leg veins, and (if possible) bilateral impedance plethysmography; PE by ventilation-perfusion lung scan;
    Exclusion criteria other indications for, or contraindication to, long-termanticoagulant therapy; need for long-term treatment with nonsteroidal anti-inflammatory drugs, ticlopidine, sulfinpyrazone, dipyridamole, or more than 160 mg of aspirin per day; familial bleeding disorder; major psychiatric disorder; pregnant or could become pregnant
    Baseline characteristics
    time of randomization 1 months 

    Method and design

    Randomized effectives NA / NA (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 11 months (after randomizatio)
    Number of centre 13
    Geographic area Canada, US
    Primary endpoint recurrent VTE


    Results

    No results available for this trial - no clinical endpoint reported



    Reference(s)

    Trials register # NA
    • Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor.. J Thromb Haemost 2004;2:743-9
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend